What is ARIA, and why does it matter for treatment?
Amyloid-related imaging abnormalities are the defining safety consideration of the anti-amyloid antibody class — and the reason MRI surveillance is built into treatment.
ARIA is the price of admission for amyloid clearance. Most cases are mild; a small minority are serious; all require monitoring.
ARIA stands for amyloid-related imaging abnormalities. It is the name given to a set of changes that can show up on brain MRI in people receiving anti-amyloid antibody therapy. Understanding ARIA is essential to understanding why these treatments require the surveillance and specialist support they do.
The two forms
ARIA comes in two forms, distinguished by what shows up on MRI:
- ARIA-E — areas of edema, or fluid buildup, in the brain. These typically appear as bright regions on certain MRI sequences.
- ARIA-H — small areas of bleeding, or microhemorrhage, often appearing as small dark spots on MRI.
Both forms are most commonly detected by surveillance MRI rather than by symptoms. A meaningful proportion of ARIA cases produce no symptoms at all.
When it happens
ARIA risk is highest in the first several months of anti-amyloid antibody therapy. The risk is not uniform across the patient population: people who carry two copies of the APOE4 gene variant have a substantially higher rate of ARIA than non-carriers, and a higher rate of symptomatic ARIA when it does occur. This is the principal reason APOE genotyping is now standard before initiating treatment.
Why surveillance matters
Most ARIA is asymptomatic and resolves with continued monitoring or temporary treatment pause. A minority of cases are clinically significant — producing headache, confusion, visual changes, or in rare cases more serious neurologic events. Because ARIA can be present without symptoms, scheduled MRIs at protocol-defined intervals are required throughout the early treatment course. The surveillance schedule is not optional; it is built into the FDA labeling and into payor coverage requirements.
How it shapes treatment
ARIA management is one of the operational reasons anti-amyloid therapy concentrates at well-resourced centers. The clinical decision tree — when to pause, when to discontinue, when to resume — requires specialist judgment, and the imaging surveillance schedule consumes MRI scanner capacity that is already constrained at most health systems. The MRI bottleneck discussed in our Signal on ARIA monitoring is a direct consequence of this surveillance requirement.
What patients should know
ARIA risk is real but, in most patients, manageable with the surveillance and clinical-judgment infrastructure that goes with anti-amyloid therapy. The risk profile is part of the conversation that any patient considering treatment should have with their treating neurologist, alongside APOE genotype results, baseline MRI findings, and the realistic expected benefits of treatment.
Key sources
- FDA prescribing information — Leqembi (lecanemab), ARIA section
- FDA prescribing information — Kisunla (donanemab), ARIA section
- Cogswell et al. and Filippi et al., consensus guidance on ARIA recognition and management